Abstract: A box includes a front receiving panel, a bottom surface panel, a rear surface panel, a top surface panel, and a front surface panel that are integrally connected one to another. Each pair of bottom side panels, rear side panels, top side panels, and front side panels are integrally connected to the respective sides of each of the bottom, rear, top, and front surface panels. The front receiving panel, the bottom and rear surface panels, and the bottom and rear side panels constitute a tray portion of the box, with the remaining panels constituting a lid portion of the box. A cut line for separating the lid portion from the tray portion is formed to pass through one or both of the rear surface panel and the top surface panel.

Abstract: A box includes a front receiving panel, a bottom surface panel, a rear surface panel, a top surface panel, and a front surface panel that are integrally connected one to another. Each pair of bottom side panels, rear side panels, top side panels, and front side panels are integrally connected to the respective sides of each of the bottom, rear, top, and front surface panels. The front receiving panel, the bottom and rear surface panels, and the bottom and rear side panels constitute a tray portion of the box, with the remaining panels constituting a lid portion of the box. A cut line for separating the lid portion from the tray portion is formed to pass through one or both of the rear surface panel and the top surface panel.

Abstract: A compound of the formula: wherein Ar is optionally substituted phenyl, etc.; n is 0, 1 or 2; R1 is hydogen atom, optionally substituted alkyl, etc.; R2 and R3 are independently optionally substituted alkyl, etc.; R4 and R5 are independently hydrogen atom or optionally substituted alkyl; R6 is hydrogen atom, hydroxy or alkyl; or a pharmaceutically acceptable salt thereof is useful as a medicament for treating retinal degenerative disorders and the like.

Abstract: A compound represented by formula (1): wherein X is a single bond or a substituted or unsubstituted lower alkylene group; Z is a saturated or unsaturated monocyclic hydrocarbon ring group or the like; and each of R1, R2, R3 and R4, which may be the same or different, is a hydrogen atom, a halogen atom, a nitro group, a cyano group, a carboxyl group, a substituted or unsubstituted alkyl group, or the like, a prodrug of said compound, or a pharmaceutically acceptable salt of said compound or prodrug has inhibitory effect on Rho kinase and hence is useful for treating diseases which are such that morbidity due to them is expected to be improved by inhibition of Rho kinase and secondary effects such as inhibition of the Na+/H+ exchange transport system caused by the Rho kinase inhibition, for example, hypertension.

Abstract: A compound of the formula: 1

Abstract: A compound of the formula: wherein Ar is optionally substituted phenyl, etc.; n is 0, 1 or 2; R1 is hydogen atom, optionally substituted alkyl, etc.; R2 and R3 are independently optionally substituted alkyl, etc.; R4 and R5 are independently hydrogen atom or optionally substituted alkyl; R6 is hydrogen atom, hydroxy or alkyl; or a pharmaceutically acceptable salt thereof is useful as a medicament for treating retinal degenerative disorders and the like.

Abstract: A compound represented by the figure (1) or a pharmaceutically acceptable salt thereof is useful as medicament for treating retinal degenerative disorders: wherein Ar is optionally substitued phenyl or optionally substituted heteroaryl;. n is 0, 1 or 2; W is —CH2NH— or —CH═N(O)—; R1, R2 and R3 are independently optionally substituted alkyl, carboxyl or alkoxycarbonyl; any two groups of R1, R2 and R3 may be taken together with the carbon atom to form optionally substituted cycloalkane; all of R1, R2 and R3 may be taken together with the adjusent carbon atom to form optionally substituted bicycloalkane or optionally substituted tricycloalkane; R4 and R5 are independently hydrogen atom or optionally substituted alkyl.